A nagy dilemma: A nem kissejtes tüdorák kemoterá piája

Translated title of the contribution: The big dilemma: The chemotherapy of nonsmall cell lung carcinoma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The most problematic area in pulmonary oncology is the chemotherapy of nonsmall cell lung carcinoma and its place in the therapeutic strategy. Chemotherapy based on the earlier alkylating agents worsened survival of NSCLC patients. That was the reason for the nihilistic approach by many colleagues toward chemotherapy in NSCLC. Today this question has been resolved. Platinum based combined chemotherapy significantly prolongs survival and improves quality of life. Other possibilities are to incorporate the new chemotherapeutic agents (taxanes, Gemcitabine, Vinorelbine, Irinotecan) into the chemotherapeutic regimens. These agents improve the response rate and the quality of life and can be safely administered in outpatient bases, although in comparison to the earlier agents the survival gain is moderate. In early stages the role of adjuvant chemotherapy is questionable. Chemotherapy, surgery and postoperative irradiation may all have a role in the case of N2 disease. In locally advanced disease the use of radiochemotherapy is recommended. In advanced NSCLC chemotherapy is suggested in good performance status. The author summarises the role of chemotherapy in NSCLC, based on literature and on his own experience.

Original languageHungarian
Pages (from-to)215-220
Number of pages6
JournalMagyar Onkologia
Volume44
Issue number3
Publication statusPublished - 2000

Fingerprint

Carcinoma
Drug Therapy
Lung
irinotecan
gemcitabine
Survival
Quality of Life
Taxoids
Alkylating Agents
Chemoradiotherapy
Adjuvant Chemotherapy
Platinum
Outpatients
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

A nagy dilemma : A nem kissejtes tüdorák kemoterá piája. / Ostoros, G.

In: Magyar Onkologia, Vol. 44, No. 3, 2000, p. 215-220.

Research output: Contribution to journalArticle

@article{d8731e13722545a9a027b1b8da5e8777,
title = "A nagy dilemma: A nem kissejtes t{\"u}dor{\'a}k kemoter{\'a} pi{\'a}ja",
abstract = "The most problematic area in pulmonary oncology is the chemotherapy of nonsmall cell lung carcinoma and its place in the therapeutic strategy. Chemotherapy based on the earlier alkylating agents worsened survival of NSCLC patients. That was the reason for the nihilistic approach by many colleagues toward chemotherapy in NSCLC. Today this question has been resolved. Platinum based combined chemotherapy significantly prolongs survival and improves quality of life. Other possibilities are to incorporate the new chemotherapeutic agents (taxanes, Gemcitabine, Vinorelbine, Irinotecan) into the chemotherapeutic regimens. These agents improve the response rate and the quality of life and can be safely administered in outpatient bases, although in comparison to the earlier agents the survival gain is moderate. In early stages the role of adjuvant chemotherapy is questionable. Chemotherapy, surgery and postoperative irradiation may all have a role in the case of N2 disease. In locally advanced disease the use of radiochemotherapy is recommended. In advanced NSCLC chemotherapy is suggested in good performance status. The author summarises the role of chemotherapy in NSCLC, based on literature and on his own experience.",
keywords = "Chemotherapy, Non small cell lung cancer, Quality of life, Survival",
author = "G. Ostoros",
year = "2000",
language = "Hungarian",
volume = "44",
pages = "215--220",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - A nagy dilemma

T2 - A nem kissejtes tüdorák kemoterá piája

AU - Ostoros, G.

PY - 2000

Y1 - 2000

N2 - The most problematic area in pulmonary oncology is the chemotherapy of nonsmall cell lung carcinoma and its place in the therapeutic strategy. Chemotherapy based on the earlier alkylating agents worsened survival of NSCLC patients. That was the reason for the nihilistic approach by many colleagues toward chemotherapy in NSCLC. Today this question has been resolved. Platinum based combined chemotherapy significantly prolongs survival and improves quality of life. Other possibilities are to incorporate the new chemotherapeutic agents (taxanes, Gemcitabine, Vinorelbine, Irinotecan) into the chemotherapeutic regimens. These agents improve the response rate and the quality of life and can be safely administered in outpatient bases, although in comparison to the earlier agents the survival gain is moderate. In early stages the role of adjuvant chemotherapy is questionable. Chemotherapy, surgery and postoperative irradiation may all have a role in the case of N2 disease. In locally advanced disease the use of radiochemotherapy is recommended. In advanced NSCLC chemotherapy is suggested in good performance status. The author summarises the role of chemotherapy in NSCLC, based on literature and on his own experience.

AB - The most problematic area in pulmonary oncology is the chemotherapy of nonsmall cell lung carcinoma and its place in the therapeutic strategy. Chemotherapy based on the earlier alkylating agents worsened survival of NSCLC patients. That was the reason for the nihilistic approach by many colleagues toward chemotherapy in NSCLC. Today this question has been resolved. Platinum based combined chemotherapy significantly prolongs survival and improves quality of life. Other possibilities are to incorporate the new chemotherapeutic agents (taxanes, Gemcitabine, Vinorelbine, Irinotecan) into the chemotherapeutic regimens. These agents improve the response rate and the quality of life and can be safely administered in outpatient bases, although in comparison to the earlier agents the survival gain is moderate. In early stages the role of adjuvant chemotherapy is questionable. Chemotherapy, surgery and postoperative irradiation may all have a role in the case of N2 disease. In locally advanced disease the use of radiochemotherapy is recommended. In advanced NSCLC chemotherapy is suggested in good performance status. The author summarises the role of chemotherapy in NSCLC, based on literature and on his own experience.

KW - Chemotherapy

KW - Non small cell lung cancer

KW - Quality of life

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=37349061631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349061631&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:37349061631

VL - 44

SP - 215

EP - 220

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 3

ER -